|
|
Article: CytoCore Reports 3rd Quarter Loss While Ramping Up Clinical Trials.
- Article from:
- Business Wire
- Article date:
- November 20, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Biomarker Discovery Supports Early Reproductive Cancer Detection Testing
CHICAGO -- Owing to a ramp-up of clinical trial operations, manufacturing processes for the E2 Collector and expanded development of a groundbreaking screening system for the early detection of uterine cancer, CytoCore, Inc. (OTCBB:CYCR) reported a loss for the 3rd quarter ended September 30, 2006.
The late-stage bioscientific research company recorded a 3rd-quarter loss of $1.325 million, or $.00 per share, compared with a loss of $308,000, or $.00 per share, during the same quarter ended September 30, 2005.
For the nine-month period ending September 30, 2006, the ...